<DOC>
	<DOCNO>NCT01442935</DOCNO>
	<brief_summary>The main objective compare resection rate ( R0 R1 ) hepatic metastasis experimental arm ( tri chemotherapy plus targeted therapy ) versus control arm ( bi chemotherapy plus targeted therapy ) ; arm target therapy select accord K-Ras status patient 's tumor . The secondary objective evaluate objective response rate ( CR PR ) 4 cycle treatment , accord RECIST V1.1 evaluation scale . - rate complete remission ( CR ) 6 month last study treatment ( hepatic surgery last chemotherapy cycle ) . - specific rate resection R0 , R1 , R2 . - complete pathological response Rate , - relapse-free survival rate ( R0 R1 ) resect patient , - response duration non-resected patient , - toxicity accord CTC AE V4 scale except neurotoxicity evaluate Levi scale , - post operative complication use DINDO classification , - progression-free survival ( PFS ) overall survival ( OS ) . The objective biological study : - evaluate tumor-related predictive factor somatic mutation ( KRAS , BRAF , TP53 ) genetic amplification relate factor ( EGFR ) , - evaluate patient-related predictive factor connection genetic polymorphism ( Fc gamma VEGF receptor ) , - evaluate ADCC activity via immunohistochemistry order analyze lympho free progression-free survival , - study circulate tumor cell prognostic factor metastatic colorectal cancer , non- resectable presentation .</brief_summary>
	<brief_title>Chemotherapies Associated With Targeted Therapies Resection Rate Hepatic Metastases</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Histologically proven colorectal adenocarcinoma , Primary tumor colon rectum , resectable resect least 3 week randomization 4 week begin study treatment , Metastatic disease synchronous metachronous ( &gt; 3 month diagnosis primary tumor ) hepatic metastasis , Nonresectable ( respect curative intent ) hepatic metastasis presentation . This criterion must validate surgeon radiologist RCP ( Multidisciplinary cancer case presentation committee ) patient 's evaluation meeting ( either technically nonresectable metastasis ( absolute contraindication ) : i.e . impossibility resect metastasis single operation preserve least 30 % healthy liver tissue and/or impossibility preserve portal vein hepatic artery homolateral liver portal pedicle , due oncological nonresectability ( relative contraindication ) : presence &gt; 5 nodule bilateral invasion ) , Hepatic metastasis , without spread site except case ≤ 3 resectable pulmonary metastasis diameter &lt; 2 cm , detect thoracic scanner , KRas status determine randomization , Measurable disease accord RECIST V1.1 criterion , No prior treatment hepatic metastasis , Previous 5FU +/ oxaliplatinbased adjuvant chemotherapy administer colorectal tumor resection authorize complete 1 year , Age ≥ 18 &amp; ≤ 75 year Performance status : ECOG 0 1 , Life expectancy ≥ 3 month , Hemoglobin ≥ 9 g/dl , Polynuclear neutrophiles ≥ 1500/mm3 , Platelets ≥ 100 000 mm3 , Creatinemia ≤ 135 µmol/l ( 1,35 mg/dl ) Total bilirubin ≤ 1.25 time Upper Limit Normal ( ULN ) . Hepatic enzyme ASAT ALAT &lt; 5 x ULN , Negative pregnancy test woman childbearing age , Information give patient sign informed consent , Public Health insurance coverage . Non metastatic and/or non measurable disease accord RECIST v1.1 criterion . Nonresectable primary tumor ( e.g . : T4 tumor ) incomplete resection R2 . History intestinal inflammatory disease . Specific contraindication study treatment . Patient previously receive antiEGFr ( e.g. , cetuximab ) antiVEGF monoclonal antibody treatment ( e.g. , bevacizumab ) treatment irinotecan . History cancer consider cure . Stroke/CVA pulmonary embolism within 6 month inclusion . Significant concomitant disease : coagulopathy , respiratory cardiac congestive insufficiency , nonmedically controlled/unstable angina pectoris , myocardial infarction within 6 month prior study entry , arterial hypertension uncontrolled arrhythmia , severe infection . Clinical neuropathy , grade ≥1 . Patient already include another therapeutic trial use experimental molecule . Pregnant woman woman might become pregnant study lactate woman . Men woman procreate abide use contraceptive mean . Persons keep detention incapable give consent Patient unwilling unable comply medical followup require trial geographic social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Non-resectable hepatic metastasis</keyword>
	<keyword>First-line treatment</keyword>
</DOC>